Dataset Information


Inhibition of PP2A with LB-100 Enhances Efficacy of CAR-T Cell Therapy Against Glioblastoma.

ABSTRACT: Chimeric antigen receptor (CAR)-engineered T cells represent a promising modality for treating glioblastoma. Recently, we demonstrated that CAR-T cells targeting carbonic anhydrase IX (CAIX), a protein involved in HIF-1a hypoxic signaling, is a promising CAR-T cell target in an intracranial murine glioblastoma model. Anti-CAIX CAR-T cell therapy is limited by its suboptimal activation within the tumor microenvironment. LB-100, a small molecular inhibitor of protein phosphatase 2A (PP2A), has been shown to enhance T cell anti-tumor activity through activation of the mTOR signaling pathway. Herein, we investigated if a treatment strategy consisting of a combination of LB-100 and anti-CAIX CAR-T cell therapy produced a synergistic anti-tumor effect. Our studies demonstrate that LB-100 enhanced anti-CAIX CAR-T cell treatment efficacy in vitro and in vivo. Our findings demonstrate the role of LB-100 in augmenting the cytotoxic activity of anti-CAIX CAR-T cells and underscore the synergistic therapeutic potential of applying combination LB-100 and CAR-T Cell therapy to other solid tumors.


PROVIDER: S-EPMC7017120 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6827823 | BioStudies
2020-01-01 | S-EPMC7467059 | BioStudies
2014-01-01 | S-EPMC4782938 | BioStudies
1000-01-01 | S-EPMC4268575 | BioStudies
2016-01-01 | S-EPMC5183620 | BioStudies
2016-01-01 | S-EPMC5085160 | BioStudies
2012-01-01 | S-EPMC3367109 | BioStudies
2018-01-01 | S-EPMC6344461 | BioStudies
2013-01-01 | S-EPMC5189272 | BioStudies
2019-01-01 | S-EPMC6397705 | BioStudies